“Tangentiality” Not Available Unless Demonstrated In Prosecution History
Client Alert | 1 min read | 03.30.07
A per curium Federal Circuit panel decision in Cross Medical Products, Inc. v. Medtronic Sofamor Danek, Inc., et al. (No. 05-1415, March 20, 2007) finds that factual circumstances appropriate for invoking “tangentiality” to overcome a presumption that estoppel applies to a claim amendment remain very narrow and must appear in the prosecution history.
During litigation, Medtronic had focused on the prosecution history in attempting to design around one of the claims at issue by altering its original screw design to terminate threads at a position above a rod diameter. In response to indefiniteness rejections made during prosecution before the patent examiner, the applicant had amended that claim, which as originally written, did not have any particular limitation about the extent of the threading, to recite that threads extend to a depth below the diameter of the rod. The district court still found infringement by Medtronic’s redesigned screws under the doctrine of equivalents, concluding that the rationale behind the claim amendment was “no more than tangentially related to Medtronic’s new screw design.” Medtronic’s reliance on the doctrine of equivalents as barred was rejected.
Following issuance of a permanent injunction and Medtronic’s appeal, the Federal Circuit panel reverses, concluding that summary judgment of non-infringement of all asserted claims should have been entered for Medtronic with respect to the redesigned screws. The prosecution history explains that the thread depth limitation, i.e. that the “anchor seat threads extend toward the channel to a depth below the top of the stabilizer when it is in the channel,” was added to capture the manner in which the stabilizer aspect of the invention operated and thereby overcome the indefiniteness rejections. Thus, the accused equivalent, which does not include threads extending “to a depth below the top of the stabilizer” and correspondingly does not capture this aspect of the invention, relates to the amendment as shown even by the applicant’s own statements.
Insights
Client Alert | 3 min read | 11.17.26
CMS Final OPPS Rule Will Reduce Reimbursement for 340B Drugs
On November 6, 2026, the Centers for Medicare and Medicaid Services (CMS) published its final 2027 Medicare Hospital Outpatient Perspective Payment System (OPPS) rule. The rule will reduce reimbursement for 340B drugs from average sales price (ASP) plus 6% (what Medicare generally pays for Part B outpatient drugs administered by providers) to ASP minus 28%, a 32% reduction. CMS originally proposed reducing reimbursement to ASP minus 33.4%. CMS indicated that this change will better align Medicare reimbursement with hospitals’ costs of acquiring 340B drugs.
Client Alert | 9 min read | 11.17.26
Priorities and Prospects for AI Legislation in the New Congress
Client Alert | 8 min read | 11.16.26
OCC’s AI Examiner Framework: How Banks’ AI Use Can Trigger Legal Liability and Supervisory Exposure
Client Alert | 3 min read | 11.13.26
Massachusetts Trade Secret Preliminary Injunctions: Prove the Harm, Tailor the Relief
